GLP-1/glucagonInvestigational · Approved in China; not FDA-filed

Mazdutide

Dual glucagon and GLP-1 receptor agonist. Once weekly.

Mazdutide (investigational in US)·Eli Lilly / Innovent Biologics

Catalog reviewed Oct 13, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

Approved in China for obesity (June 2025) and type 2 diabetes (September 2025), where Innovent markets it. It is not FDA-approved and has not been filed in the US, so it is not available to US patients.

What to know about Mazdutide

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

FDA shortage report: In development
Investigational. Not FDA-approved.
Route & frequency: Once weekly

Indications

Investigational uses

Mazdutide (investigational in US)

Obesity; type 2 diabetes

Obesity (investigational in US)Type 2 diabetes (investigational in US)

A dual agonist of the glucagon (GCGR) and GLP-1 receptors: adding glucagon activity is intended to raise energy expenditure on top of the appetite and glycemic effects of GLP-1.

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

No approved label (investigational)

Mazdutide is investigational. See its registered studies below. Search DailyMed.

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.

Evidence

Clinical trials

39 of 43 registered studies indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.